| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 2, 2006
Revised on December 19, 2006
Accepted on January 25, 2007
From the From the Departments of Cardiovascular Medicine (MN, KS, YF, YI, YK, HS) and Microbiology and Immunology (NI, KS), Tohoku University Graduate School of Medicine, Sendai, Japan.
* To whom correspondence should be addressed. E-mail: fukumoto{at}cardio.med.tohoku.ac.jp.
We have recently demonstrated that endogenous erythropoietin (Epo)/Epo receptor (EpoR) system plays an important protective role in hypoxia-induced pulmonary hypertension. However, it remains to be examined whether vascular EpoR system contributes to angiogenesis in response to ischemia. We examined angiogenesis in EpoR-/--rescued mice that lack EpoR in most organs including cardiovascular system except erythroid-lineage cells. Two weeks after femoral artery ligation, blood flow recovery, activation of VEGF/VEGF receptor system, and mobilization of endothelial progenitor cells were all impaired in EpoR-/--rescued mice as compared with wild-type (WT) mice. Bone marrow (BM) transplantation with WT-BM cells in EpoR-/--rescued mice partially but significantly improved blood flow recovery after hindlimb ischemia. The extent of VEGF upregulation and the number of BM-derived cells in ischemic tissue were significantly less in EpoR-/--rescued mice compared with WT mice even after BM reconstitution with WT-BM cells. Similarly, the recovery of blood flow was significantly impaired in recipient EpoR-/--rescued mice that had been transplanted with WT-BM or EpoR-/--rescued-BM as compared with recipient WT mice. Furthermore, the Matrigel implantation assay and aortic ring assay showed that microvessel growth in vitro was significantly reduced in EpoR-/--rescued mice as compared with WT mice. These results indicate that vascular EpoR system also plays an important role in angiogenesis in response to hindlimb ischemia through upregulation of VEGF/VEGF receptor system, both directly by enhancing neovascularization and indirectly by recruiting endothelial progenitor cells and/or BM-derived proangiogenic cells.
Related Article:
This article has been cited by other articles:
![]() |
T. E. Perry, M. Song, D. J. Despres, S. M. Kim, H. San, Z.-X. Yu, N. Raghavachari, J. Schnermann, R. O. Cannon III, and D. Orlic Bone marrow-derived cells do not repair endothelium in a mouse model of chronic endothelial cell dysfunction Cardiovasc Res, November 1, 2009; 84(2): 317 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schroder, A. Kohnen, A. Aicher, E. A. Liehn, T. Buchse, S. Stein, C. Weber, S. Dimmeler, and R. P. Brandes NADPH Oxidase Nox2 Is Required for Hypoxia-Induced Mobilization of Endothelial Progenitor Cells Circ. Res., September 11, 2009; 105(6): 537 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Rundqvist, E. Rullman, C. J. Sundberg, H. Fischer, K. Eisleitner, M. Stahlberg, P. Sundblad, E. Jansson, and T. Gustafsson Activation of the erythropoietin receptor in human skeletal muscle Eur. J. Endocrinol., September 1, 2009; 161(3): 427 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-H. Huang, Y.-H. Chen, C.-H. Wang, J.-S. Chen, H.-Y. Tsai, F.-Y. Lin, W.-Y. Lo, T.-C. Wu, M. Sata, J.-W. Chen, et al. Matrix Metalloproteinase-9 Is Essential for Ischemia-Induced Neovascularization by Modulating Bone Marrow-Derived Endothelial Progenitor Cells Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1179 - 1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, H. Okada, G. Takemura, M. Esaki, H. Kobayashi, H. Kanamori, I. Kawamura, R. Maruyama, T. Fujiwara, H. Fujiwara, et al. Sustained Release of Erythropoietin Using Biodegradable Gelatin Hydrogel Microspheres Persistently Improves Lower Leg Ischemia J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2378 - 2388. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Brunner, J. Winogradow, B. C. Huber, M.-M. Zaruba, R. Fischer, R. David, G. Assmann, N. Herbach, R. Wanke, J. Mueller-Hoecker, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis FASEB J, February 1, 2009; 23(2): 351 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer Anemia and Cerebral Outcomes: Many Questions, Fewer Answers Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kobayashi, S. Minatoguchi, S. Yasuda, N. Bao, I. Kawamura, M. Iwasa, T. Yamaki, S. Sumi, Y. Misao, H. Ushikoshi, et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair Cardiovasc Res, September 1, 2008; 79(4): 611 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shimokawa Bone Marrow-Derived Matrix Metalloproteinase-14: A Novel Target for Plaque Stability Circulation, February 19, 2008; 117(7): 863 - 865. [Full Text] [PDF] |
||||
![]() |
K. Satoh and B. C. Berk Circulating smooth muscle progenitor cells: novel players in plaque stability Cardiovasc Res, February 1, 2008; 77(3): 445 - 447. [Full Text] [PDF] |
||||
![]() |
J. Menne, J.-K. Park, N. Shushakova, M. Mengel, M. Meier, and D. Fliser The Continuous Erythropoietin Receptor Activator Affects Different Pathways of Diabetic Renal Injury J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2046 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stamm ICVTS on-line discussion B Don't give up, yet! Interactive CardioVascular and Thoracic Surgery, June 1, 2007; 6(3): 297 - 297. [Full Text] [PDF] |
||||
![]() |
P. Madeddu and C. Emanueli Switching on Reparative Angiogenesis: Essential Role of the Vascular Erythropoietin Receptor Circ. Res., March 16, 2007; 100(5): 599 - 601. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |